Patient Quality of Life

ACS CAN advocates for policies that improve the lives of cancer patients by making treatment of their pain and other symptoms and coordination of their care standard protocol throughout their treatment for cancer, starting at the point of diagnosis.

 

Patient Quality of Life Resources:

This table lists key studies and review articles that examine the effect that the addition of palliative care has on overall patient costs. While results vary, the addition of palliative care typically either reduces overall costs or is cost neutral.

Our latest survey finds that female cancer patients are less satisfied with the quality of their cancer care than male cancer patients and are more likely to report that their symptoms were not taken seriously and that they had to prove their symptoms to providers.

ACS CAN submitted comments regarding the Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids. While we support certain changes in the Guideline - including a clearer exemption for cancer patients and patients receiving palliative care - we continue to have concerns about the misapplication of this and the previous Guideline. 

ACS CAN supports balanced policies that address the public health concerns relevant to the opioid epidemic,  that do not harm patient access to  medications that they need to treat pain appropriately. 

Palliative care is coordinated patient care that treats the patient as well as the disease.  It provides cancer patients and their caregivers an extra layer of support, making available a team of experts focused on relieving pain, managing emotional stress and offering other supportive services.

In August-September 2019, the American Cancer Society Cancer Action Network (ACS CAN) — through its Survivor Views Project  — conducted a survey of cancer patients and survivors to determine whether they were asking for and getting appropriate palliative care treatment. 

ACS CAN submitted comments to FDA regarding the use of opioids at higher doses, in response to an FDA request for comments.